Hybio Pharmaceutical's (SHE:300199) Pingshan Branch in China passed the U.S. Food and Drug Administration's inspection after no deficiencies requiring regulatory action were found, according to a Shenzhen bourse filing on Thursday.
The routine inspection was conducted between June 18 and June 26 in compliance with current good manufacturing practice (cGMP) requirements for drug manufacturing.
The Chinese pharmaceutical company's shares slipped 1% during the afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.